Regulation of renovascular adenosine 3′,5′-cyclic monophosphate in spontaneously hypertensive rats

Hypertension

Volumn 54, Issue 2, 2009, Pages 270-277

  Jackson, Edwin K ^a   Mi, Zaichuan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

3',5' cAMP; Adenylyl cyclase; Forskolin; Isoproterenol; Phosphodiesterase; Spontaneously hypertensive rats; Wistar Kyoto rats

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLIC AMP; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; MILRINONE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; 8 METHOXYMETHYL 3 ISOBUTYL 1 METHYLXANTHINE; 8-METHOXYMETHYL-3-ISOBUTYL-1-METHYLXANTHINE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEREDITARY HYPERTENSION; HYPERTENSION; ISOLATED KIDNEY; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PHYSIOLOGY; PROBABILITY; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VASCULARIZATION;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CYCLIC AMP; DISEASE MODELS, ANIMAL; FORSKOLIN; HYPERTENSION, RENOVASCULAR; ISOPROTERENOL; KIDNEY; MALE; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REFERENCE VALUES; RENAL CIRCULATION; SENSITIVITY AND SPECIFICITY; XANTHINES;

EID: 68549090858     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.130542     Document Type: Article

References (24)

1. Heuze-Joubert I, Mennecier P, Simonet S, Laubie M, Verbeuren TJ. Effect of vasodilators, including nitric oxide, on the release of cGMP and cAMP in the isolated perfused rat kidney. Eur J Pharmacol. 1992;220: 161-171.
2. 2 actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol. 2000;279:F755-F764.
3. Sandner P, Kornfeld M, Ruan X, Arendshorst WJ, Kurtz A. Nitric oxide/cAMP interactions in the control of rat renal vascular resistance. Circ Res. 1999;84:186-192.
4. Chatziantoniou C, Ruan X, Arendshorst WJ. Interactions of cAMP-mediated vasodilators with angiotensin II in rat kidney during hypertension. Am J Physiol. 1993;265:F845-F852.
5. s protein interactions in isolated renal resistance arterioles of spontaneously hypertensive rats. Hypertension. 1999;34:1134-1140.
6. Chatziantoniou C, Ruan X, Arendshorst WJ. Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proc Natl Acad Sci U S A. 1995;92:2924-2928.
7. Mokkapatti R, Vyas SJ, Romero GG, Mi Z, Inoue T, Dubey RK, Gillespie DG, Stout AK, Jackson EK. Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats. J Pharmacol Exp Ther. 1998;287:223-231.
8. Vyas SJ, Mi Z, Jackson EK. The inhibitory effect of angiotensin II on stimulus-induced release of cAMP is augmented in the genetically hypertensive rat kidney. J Pharmacol Exp Ther. 1996;279:114-119.
9. Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV. Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity. Mol Pharmacol. 1970;6:597-603.
10. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci. 1990;11:150-155.
11. Wells JN, Miller JR. Methylxanthine inhibitors of phosphodiesterases. Methods Enzymol. 1988;159:489-496.
12. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol. 1986;29:506-514.
13. Carcillo JA, Herzer WA, Mi Z, Thomas NJ, Jackson EK. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. J Pharmacol Exp Ther. 1996;279:1197-1204.
14. Begany DP, Carcillo JA, Herzer WA, Mi Z, Jackson EK. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther. 1996;278:37-41.
15. Jackson EK, Mi Z. Preglomerular microcirculation expresses the cAMP-adenosine pathway. J Pharmacol Exp Ther. 2000;295:23-28.
16. Dubey RK, Gillespie DG, Jackson EK. Cyclic AMP-adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells. Hypertension. 1998;31:296-302.
17. Goldman SJ, Dickinson ES, Slakey LL. Effect of adenosine on synthesis and release of cyclic AMP by cultured vascular cells from swine. J Cyclic Nucleotide Protein Phosphor Res. 1983;9:69-78.
18. Scheinman SJ, Coulson R. Effect of perfusate phosphate concentration on responses to PTH in isolated rat kidney. Am J Physiol. 1984;246: F907-F915.
19. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
20. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
21. Tawar U, Kotlo K, Jain S, Shukla S, Setty S, Danziger RS. Renal phospho-diesterase 4B is activated in the Dahl salt-sensitive rat. Hypertension. 2008;51:762-766.
22. Chatziantoniou C, Arendshorst WJ. Angiotensin and thromboxane in genetically hypertensive rats: renal blood flow and receptor studies. Am J Physiol. 1991;261:F238-F247.
23. Arendshorst WJ, Beierwaltes WH. Renal and nephron hemodynamics in spontaneously hypertensive rats. Am J Physiol. 1979;236:F246-F251.
24. Beirewaltes WH, Arendshorst WJ. Renal function of conscious sponta-neously hypertensive rats. Circ Res. 1978;42:721-726.